ADAM9 shRNA lentivirus

ADAM9 shRNA lentivirus is an experimental gene therapy agent designed to silence the expression of A disintegrin and metalloproteinase 9 (ADAM9). ADAM9 is a transmembrane protein often upregulated in various cancers, including prostate cancer, where it promotes tumor progression and survival under stress. The therapeutic utilizes a lentiviral vector to deliver small hairpin RNA (shRNA) that triggers RNA interference against ADAM9 mRNA. Knockdown of ADAM9 leads to cell cycle arrest in the G1 phase, reduced expression of REG4, and induction of p21(Cip1/WAF1), which subsequently inhibits cyclin D1. In preclinical models, this agent has demonstrated the ability to inhibit prostate cancer cell proliferation and suppress tumor growth in bone metastasis models.

Other names

lentivirus-delivered small hairpin RNA targeting ADAM9ADAM9 knockdown lentivirusADAM-9 knockdown lentivirusADAM 9 knockdown lentivirusADAM9-targeting shRNA lentiviral vectorADAM-9-targeting shRNA lentiviral vectorADAM 9-targeting shRNA lentiviral vector